We remain fully committed to developing a functional cure for all patients with insulin - requiring diabetes. (viacyte.com)
The company's lead PEC - DirectTM product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications. (viacyte.com)
San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today that the U.S. Food and Drug Administration (FDA) has allowed the company's Investigational New Drug Application (IND) for the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a potential cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications. (viacyte.com)